Should you buy Northwest Biotherapeutics stock now?
No, the technical signal for Northwest Biotherapeutics is currently Strong Sell. Northwest Biotherapeutics trades at $0.15 as of Oct 7, 2026. The technical analysis shows the following: MACD is negative (bearish trend) at -0.006 with falling momentum (signal: -0.005); RSI is at 31.7 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average). The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Northwest Biotherapeutics stock?
There is currently no active analyst price target for Northwest Biotherapeutics.
Is Northwest Biotherapeutics a dividend stock?
No, Northwest Biotherapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Northwest Biotherapeutics stock?
Northwest Biotherapeutics is rated as a stock in the risk category Speculative. the annual standard deviation is 65.2%, which classifies the stock as Speculative.
Is Northwest Biotherapeutics overvalued?
Northwest Biotherapeutics has the following valuation ratios: a P/S ratio of 117.7, a P/B ratio of 75.6.
Is Northwest Biotherapeutics overbought?
No, Northwest Biotherapeutics is not overbought. RSI is at 31.7 (neutral zone). The technical indicators show: RSI is at 31.7 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 8.8% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Northwest Biotherapeutics earnings report?
The date of the next earnings report for Northwest Biotherapeutics has not been published yet. Check the company's investor calendar for updates.
Is Northwest Biotherapeutics shorted?
Yes, Northwest Biotherapeutics is shorted with 15.1% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Northwest Biotherapeutics stock?
Yes, insiders are net buyers of Northwest Biotherapeutics – they are buying more shares than they are selling. Across the last 20 reported transactions, the split is 9 purchases and 11 sales, with a net 5,816,822 $ bought. Active buyers include MALIK NAVID, Farmer Robert A, Cognate Bioservices, Inc. and others. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is Northwest Biotherapeutics a good stock?
Based on our total score, Northwest Biotherapeutics is rated as a disastrous stock with a total score of 7 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 2/100, Quality: 10/100, Momentum: 11/100. In addition: technical signal: Strong Sell. Whether Northwest Biotherapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Northwest Biotherapeutics stock?
The outlook for Northwest Biotherapeutics based on current data: the stock is in a downtrend (below SMA50 and SMA200). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Northwest Biotherapeutics stock falling?
Northwest Biotherapeutics is falling right now. The technical indicators show: the price is 8.8% below the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 15.1% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Northwest Biotherapeutics go?
There is currently no active analyst price target for Northwest Biotherapeutics. The stock has traded between $0.14 and $0.34 over the last 52 weeks. The price is 57.1% below the 52-week high, which can indicate potential if the underlying fundamentals are intact. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Northwest Biotherapeutics fall?
The stock has traded as low as $0.14 over the last 52 weeks — that is 4.1% below the current price of $0.15. The biggest decline (drawdown) in the same period was 58.8% from high to low. Within a year, the price typically swings about ±65.2% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Northwest Biotherapeutics do?
Northwest Biotherapeutics, Inc. develops personalized immune treatments for cancer. The company does not yet earn money from selling approved products. Instead, it is still developing and testing its treatments, which is normal for a biotech company at this stage.
Their main ... The company belongs to the Healthcare sector, more specifically the Biotechnology industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Northwest Biotherapeutics as an investment.
Did Northwest Biotherapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Northwest Biotherapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Northwest Biotherapeutics making money or losing money?
We have no current profitability data for Northwest Biotherapeutics. See the latest report in the earnings history above.
Can Northwest Biotherapeutics go bankrupt?
The bankruptcy risk of Northwest Biotherapeutics is rated as elevated. Altman Z2 (a model for assessing financial distress) is -74.14 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 4 — which is average. Debt relative to equity is 1,000% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Northwest Biotherapeutics have a lot of debt?
Yes, Northwest Biotherapeutics has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 1,000%. For the healthcare sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.